Research programme: neuroimmunophilin ligands - MGI Pharma
Alternative Names: FKBP neuroimmunophilin ligands - MGI Pharma; Immunophilin ligands - MGI Pharma; NIL programme - MGI PharmaLatest Information Update: 03 Sep 2007
At a glance
- Originator Johns Hopkins University
- Class
- Mechanism of Action Immunophilin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alopecia; Cognition disorders; Deafness; Erectile dysfunction; Neurological disorders
Most Recent Events
- 03 Sep 2007 Discontinued - Preclinical for Alopecia in USA (PO)
- 03 Sep 2007 Discontinued - Preclinical for Cognition disorders in USA (PO)
- 03 Sep 2007 Discontinued - Preclinical for Deafness in USA (PO)